{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:59:44Z","timestamp":1785556784976,"version":"3.56.0"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12689"],"award-info":[{"award-number":["24K12689"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12655"],"award-info":[{"award-number":["24K12655"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10293"],"award-info":[{"award-number":["24K10293"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp;amp; Neck"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimal treatment for non\u2010metastatic unresectable salivary duct carcinoma (SDC) remains unclear. We compared outcomes of upfront biomarker\u2010targeted systemic therapy and radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the Joint SDC Study Group registry. Thirty\u2010one patients with centrally confirmed non\u2010metastatic unresectable SDC were classified by initial treatment (radiotherapy or systemic therapy). Systemic therapy included trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy. Progression\u2010free survival (PFS) and overall survival (OS) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Systemic therapy showed better PFS than radiotherapy (3\u2010year PFS 47.6% vs. 30.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031) without OS difference. Trastuzumab plus docetaxel showed the highest response rate (75%) and enabled curative\u2010intent treatment in all cases, with the best PFS (3\u2010year 87.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given the retrospective design and limited sample size, these findings should be regarded as hypothesis\u2010generating. An upfront trastuzumab\u2010based therapy followed by curative\u2010intent treatment may be a promising option for selected patients with HER2\u2010positive unresectable SDC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hed.70416","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:05:56Z","timestamp":1785553556000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker\u2010Driven Initial Systemic Therapy Enabling Curative\u2010Intent Treatment in Non\u2010Metastatic Unresectable Salivary Duct Carcinoma: A Multi\u2010Institutional Retrospective Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-5332","authenticated-orcid":false,"given":"Satoshi","family":"Kano","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Faculty of Medicine and Graduate School of Medicine, Hokkaido University  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3783-9961","authenticated-orcid":false,"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoyuki","family":"Hanazawa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\/Head &amp; Neck Surgery Chiba University Graduate School of Medicine  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Tokyo Medical University Hachioji Medical Center  Hachioji Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okami","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery School of Medicine, Tokai University  Isehara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery Niigata Cancer Center Hospital  Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-7891","authenticated-orcid":false,"given":"Yushi","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-7783","authenticated-orcid":false,"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2010 Head and Neck Surgery, Faculty of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\/Head &amp; Neck Surgery Chiba University Graduate School of Medicine  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-6941","authenticated-orcid":false,"given":"Sho","family":"Iwaki","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hanyu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery School of Medicine, Tokai University  Isehara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery Niigata Cancer Center Hospital  Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0085-5098","authenticated-orcid":false,"given":"Koji","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2010 Head and Neck Surgery, Faculty of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Sekimizu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakaguro","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Nagoya University Hospital  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-9738","authenticated-orcid":false,"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-8660","authenticated-orcid":false,"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2010Head and Neck Surgery Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Multi\u2010institutional Joint SDC Study Group in Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of Salivary Gland Malignancy: ASCO Guideline","volume":"39","author":"Geiger J. L.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_3_1","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers(2026) https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?id=1437."},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary Gland Cancer: ESMO\u2010European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for Diagnosis, Treatment and Follow\u2010Up","volume":"7","author":"Herpen C.","year":"2022","journal-title":"ESMO Open"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/lary.28830","article-title":"Neutron Therapy for High\u2010Grade Salivary Carcinomas in the Adjuvant and Primary Treatment Setting","volume":"131","author":"Cash H.","year":"2021","journal-title":"Laryngoscope"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/jjco\/hyaf147","article-title":"Treatment Outcomes of Definitive Radiotherapy for Unresectable Salivary Gland Cancers: A Multicenter, Retrospective Study in Northern Japan","volume":"55","author":"Ohkoshi A.","year":"2025","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/cas.13558","article-title":"A Retrospective Multicenter Study of Carbon\u2010Ion Radiotherapy for Major Salivary Gland Carcinomas: Subanalysis of J\u2010CROS 1402 HN","volume":"109","author":"Hayashi K.","year":"2018","journal-title":"Cancer Science"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/hed.28149","article-title":"Clinical Outcomes of Intensity Modulated Proton Therapy for Salivary Gland Carcinoma: High Local Control and Quality of Life Preservation","volume":"47","author":"Takano G.","year":"2025","journal-title":"Head & Neck"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and Histogenetic Roles of Gene Alteration and the Expression of Key Potentially Actionable Targets in Salivary Duct Carcinomas","volume":"9","author":"Shimura T.","year":"2018","journal-title":"Oncotarget"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker Immunoprofile in Salivary Duct Carcinomas: Clinicopathological and Prognostic Implications With Evaluation of the Revised Classification","volume":"8","author":"Takase S.","year":"2017","journal-title":"Oncotarget"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A Clinicopathological Study and Prognostic Factor Analysis of 177 Salivary Duct Carcinoma Patients From The Netherlands","volume":"143","author":"Boon E.","year":"2018","journal-title":"International Journal of Cancer"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","article-title":"Salivary Duct Carcinomas Can Be Classified Into Luminal Androgen Receptor\u2010Positive, HER2 and Basal\u2010Like Phenotypes","volume":"61","author":"Di Palma S.","year":"2012","journal-title":"Histopathology"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A Prospective Phase II Study of Combined Androgen Blockade in Patients With Androgen Receptor\u2010Positive Metastatic or Locally Advanced Unresectable Salivary Gland Carcinoma","volume":"29","author":"Fushimi C.","year":"2018","journal-title":"Annals of Oncology"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","article-title":"Apalutamide and Goserelin for Androgen Receptor\u2010Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU","volume":"30","author":"Honma Y.","year":"2024","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jjco\/hyaf106","article-title":"Multicenter Phase II Trial of Trastuzumab and Docetaxel for HER2\u2010Positive Salivary Gland Cancer","volume":"55","author":"Kano S.","year":"2025","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone Acetate in Patients With Castration\u2010Resistant, Androgen Receptor\u2010Expressing Salivary Gland Cancer: A Phase II Trial","volume":"39","author":"Locati L. D.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2\u2010Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi H.","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00595-021-02403-5","article-title":"Indications for Conversion Hepatectomy for Initially Unresectable Colorectal Cancer With Liver Metastasis","volume":"52","author":"Sugiyama M.","year":"2022","journal-title":"Surgery Today"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40792-023-01619-6","article-title":"Conversion Surgery After Lenvatinib Treatment for Anaplastic Thyroid Carcinoma: A Case Report","volume":"9","author":"Yamazaki H.","year":"2023","journal-title":"Surgical Case Reports"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10120-023-01452-8","article-title":"Oncological Outcomes of Conversion Therapy in Gastric Cancer Patients With Peritoneal Metastasis: A Large\u2010Scale Retrospective Cohort Study","volume":"27","author":"Yang Z.","year":"2024","journal-title":"Gastric Cancer"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/hed.28196","article-title":"Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma","volume":"47","author":"Nagano A.","year":"2025","journal-title":"Head & Neck"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.anl.2026.03.001","article-title":"Conversion Surgery Following Trastuzumab and Docetaxel Combination Therapy for Unresectable HER2\u2010Positive Parotid Gland Cancer","volume":"53","author":"Kano S.","year":"2026","journal-title":"Auris, Nasus, Larynx"},{"key":"e_1_2_12_23_1","first-page":"225","volume-title":"WHO Classification of Tumours Editorial Board","author":"Chiosea S.","year":"2024"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO\u2010College of American Pathologists Guideline Update","volume":"41","author":"Wolff A. C.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer E. A.","year":"2009","journal-title":"European Journal of Cancer"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/cncr.34892","article-title":"A Phase 2 Multicenter Study of Docetaxel\u2010PM and Trastuzumab\u2010Pkrb Combination Therapy in Recurrent or Metastatic Salivary Gland Carcinomas","volume":"129","author":"Lee J.","year":"2023","journal-title":"Cancer"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.30179","article-title":"Subsets of Salivary Duct Carcinoma Defined by Morphologic Evidence of Pleomorphic Adenoma, PLAG1 or HMGA2 Rearrangements, and Common Genetic Alterations","volume":"122","author":"Chiosea S. I.","year":"2016","journal-title":"Cancer"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II Study of Enzalutamide for Patients With Androgen Receptor\u2010Positive Salivary Gland Cancers (Alliance A091404)","volume":"40","author":"Ho A. L.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The Impact of HER2\u2010Low Expression in Salivary Duct Carcinoma: Clinicopathologic Features, Survival Outcomes, and Association With Androgen Receptor\u2010Targeted Therapy","volume":"165","author":"Kano S.","year":"2025","journal-title":"Oral Oncology"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hed.70416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:06:07Z","timestamp":1785553567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.70416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":28,"alternative-id":["10.1002\/hed.70416"],"URL":"https:\/\/doi.org\/10.1002\/hed.70416","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2026-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hed.70416"}}